Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology results in significant reduction in tumor growth (p<0.0001) Combination of nanoparticles with immune checkpoint inhibitor (anti-PD1) shows even more pronounced improvement, synergistic control of tumor growth with long-term complete remission of tumor in many cases Combination therapy may help to render more solid tumor patients responsive to anti-PD1 therapies (i ...